New tools for Alzheimer’s research: [Pyr³] β-Amyloid (3-42) peptide and aggregation kit

AggreSure™ [Pyr³] β-Amyloid (3-42), Human

Catalog #: AS-72277 

AnaSpec’s AggreSure™ [Pyr³] β-Amyloid (3-42) is a research-grade peptide provided in a purified, lyophilized form, suitable for in vitro studies of amyloid aggregation and neurotoxicity. This product is ideal for researchers investigating the biophysical behavior of pyroglutamate-modified Aβ species and their role in Alzheimer’s disease pathology.

Key features:

• Guaranteed to Aggregate
• Net peptide amounts for accurate quantities
• Aggresure™ β-Amyloid 1-40 & 1-42 also available

Peptide Details

SensoLyte® Thioflavin T [Pyr³] β-Amyloid (3-42) Aggregation Kit – Fluorimetric

Catalog #: AS-72276

This ready-to-use kit provides a fluorimetric assay to monitor the aggregation of [Pyr³] β-Amyloid (3-42) using Thioflavin T dye.

Key features:

• Optimized conditions for fibril formation
• Minimal hands-on time
• Reliable performance with detailed protocols and controls

The kit includes:

• Pre-treated monomeric [Pyr³] β-Amyloid (3-42)
• Thioflavin T dye
• Two known inhibitors (Morin and Phenol Red)
• Assay buffer and solvent

Perfect for screening aggregation inhibitors and studying fibrillation kinetics, this kit is a valuable tool for Alzheimer’s research labs.

Assay Kit Details

Why [Pyr³] β-Amyloid (3-42)?

A pathologically relevant peptide in Alzheimer’s disease

[Pyr³] β-Amyloid (3-42) is a naturally occurring, N-terminally truncated and pyroglutamate-modified form of the amyloid-β peptide. It accounts for approximately a quarter of the amyloid in brain plaques of individuals with Alzheimer’s disease (AD). This specific form arises through enzymatic cleavage and subsequent modification of Aβ(1-42), resulting in a peptide that begins at position 3 and features a pyroglutamate residue at the N-terminus.

Distinct biophysical and pathological properties

Compared to the full-length Aβ(1-42), [Pyr³] Aβ(3-42) exhibits:

• Increased aggregation propensity: It forms fibrils and oligomers more rapidly. ¹
• Greater neurotoxicity: It has been shown to induce stronger synaptic dysfunction and cellular toxicity.²
• Enhanced stability: The pyroglutamate modification makes the peptide more resistant to enzymatic degradation, allowing it to persist longer in neural tissue.³

These properties contribute to its early accumulation in the disease process, even before tau pathology becomes prominent.⁴

A valuable target for Alzheimer’s research

Due to its pathological relevance and distinct behavior, [Pyr³] Aβ(3-42) is increasingly recognized as a critical target for therapeutic development and biomarker discovery. Studying its aggregation kinetics and interactions with inhibitors can provide insights into:

• The mechanisms of amyloid plaque formation
• The development of aggregation-blocking compounds
• The design of early diagnostic tools

AnaSpec’s new peptide and aggregation kit offer researchers standardized, high-quality tools to explore these questions under controlled experimental conditions.

Availability

Both products are developed, manufactured, and distributed by AnaSpec, ensuring consistent quality and scientific reliability. They are available now for direct purchase through AnaSpec’s catalog.

Browse our AD research products

References

1. Nath, S., Buell, A. K. & Barz, B. Pyroglutamate-modified amyloid β(3–42) monomer has more β-sheet content than the amyloid β(1–42) monomer. Phys. Chem. Chem. Phys. 25, 16483–16491 (2023).
2. Cho, I. et al. Solid-phase synthesis and pathological evaluation of pyroglutamate amyloid-β3-42 peptide. Sci Rep 13, 505 (2023).
3. Moro, M. L. et al. Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease. acta neuropathol commun 6, 3 (2018).
4. Zagorski, K. et al. Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer’s Disease. IJMS 24, 9797 (2023).